In this review:
COVID-19 in MS patients
Dimethyl fumarate-induced lymphocyte count drop and clinical effectiveness in RRMS
aHSCT vs alemtuzumab for RRMS
Rituximab vs glatiramer acetate in SPMS
Mesenchymal stem cell transplantation in active progressive MS
Concussion in adolescence and the risk of MS
Sustained disease remission after discontinuation of DMTs in RRMS
Siponimod improves cognitive outcomes in SPMS
Amantadine, modafinil, and methylphenidate do not reduce fatigue in MS
Effects of ibudilast on MRI measures in the SPRINT-MS study
Please login below to download this issue (PDF)